| Title: |
Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma |
| Authors: |
Harba, Alia; Moinard-Butot, Fabien; Auclin, Edouard; Barthélémy, Philippe; Noel, Johanna; Dumont, Clément; Gauthier, Hélène; Huillard, Olivier; Jaffrelot, Loïc; Seisen, Thomas; Joly, Charlotte; Tournigand, Christophe; Bennamoun, Mostefa; Roulleaux-Dugage, Matthieu; Cancel, Mathilde; Heurtier, Victor; Lardjani, Hamid; Oudard, Stéphane; Thibault, Constance |
| Contributors: |
Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO); Sorbonne Université (SU); Institut de Cancérologie de Strasbourg Europe (ICANS); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institut Universitaire de Cancérologie Sorbonne Université (IUC); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS); Groupe de Recherche Clinique Onco-Urologie Prédictive (GRC 5); MetaboHUB-Clermont; MetaboHUB; Plateforme Exploration du Métabolisme (PFEM); Institut National de la Recherche Agronomique (INRA)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-MetaboHUB-Clermont; MetaboHUB-MetaboHUB; MetaboHUB-MetaboHUB-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA); Institut Mutualiste de Montsouris (IMM); Niche, Nutrition, Cancer et métabolisme oxydatif (N2Cox); Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM); Service d'oncologie médicale; Centre Hospitalier Régional Universitaire de Tours (CHRU Tours); Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité) |
| Source: |
ISSN: 1558-7673 ; Clinical Genitourinary Cancer ; https://hal.sorbonne-universite.fr/hal-05500432 ; Clinical Genitourinary Cancer, 2026, pp.102506. ⟨10.1016/j.clgc.2026.102506⟩. |
| Publisher Information: |
CCSD; Elsevier |
| Publication Year: |
2026 |
| Collection: |
Université François-Rabelais de Tours: HAL |
| Subject Terms: |
Bone metastases; Bone-targeting agents; Clear Cell renal Cell Carcinoma; First-line treatment combinations; Skeletal-related events; [SDV.CAN]Life Sciences [q-bio]/Cancer; [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy |
| Description: |
International audience ; Bone metastases affect one-third of patients with metastatic clear cell renal cell carcinoma and remain a major cause of morbidity. In this multicenter real-world study of 124 patients treated with first-line ICI-ICI or ICI-TKI combinations, both strategies showed comparable outcomes. Bone progression and skeletal events remained frequent, with bone-targeting agents independently associated with improved bone progression-free survival. Background: Bone metastases occur in one third of patients with metastatic clear cell renal cell carcinoma (mccRCC) and are associated with poor prognosis. Optimal first-line treatment for this subgroup of patients remains undefined. Methods: We conducted a multicenter retrospective study of patients with bone-metastatic (BM + ) mccRCC treated with first-line immune checkpoint inhibitor (ICI)-based combinations between January 2015 and February 2024 across 8 French centers. The primary endpoint was time to next treatment (TTNT). Secondar y endpoints included overall sur vival (OS), bone progression-free survival (bPFS), incidence of skeletal-related events (SREs) and changes in bone pain. Results: A total of 124 patients were included; 55% received ICI-ICI and 45% an ICI plus a tyrosine kinase inhibitor (TKI). Median follow-up was 36.8 months. Median TTNT was 11.7 months (95% CI, 8.38-20.0), OS 28.8 months (95% CI, 23.7-40.2) and bPFS 11.7 months (95% CI, 7.69-21.7). Median TTNT was numerically longer with ICI-TKI compared to ICI-ICI (17.9 vs. 8.5 months; P = .40), with no significant difference in OS or bPFS between treatment groups. SREs occurred in 32% of patients. Bone progression was observed in 48%, with a concomitant SRE in 54% mostly involving preexisting lesions (78%). Bone pain improved in 45% of evaluable patients. No significant differences were observed between treatment groups for SRE incidence or bone pain improvement. Hypercalcemia was associated with shorter OS and bPFS, while bone-only disease correlated with improved OS. Use of ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/j.clgc.2026.102506 |
| Availability: |
https://hal.sorbonne-universite.fr/hal-05500432; https://hal.sorbonne-universite.fr/hal-05500432v1/document; https://hal.sorbonne-universite.fr/hal-05500432v1/file/1-s2.0-S1558767326000066-main.pdf; https://doi.org/10.1016/j.clgc.2026.102506 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.66DFEC83 |
| Database: |
BASE |